People with the rare growth hormone disorder acromegaly have a significantly higher risk of developing various types of ...

People with the rare growth hormone disorder acromegaly have a significantly higher risk of developing various types of cancer, often at ages younger than typically seen in the general population, ...

Most adults with acromegaly reduced IGF-1 levels and improved acromegaly symptoms with once-monthly subcutaneous octreotide ...

The Palsonify-treated subjects maintained control, with stable growth hormone levels, symptom scores, and pituitary tumour ...

Retail chatter around Crinetics Pharmaceuticals picked up late Sunday after the company released long-term data for its oral ...

Acromegaly is a rare, progressive disease, typically caused by a tumor of the pituitary gland producing excess growth hormone and stimulating increased insulin growth factor-1 (IGF-1) levels.

The inclusion criteria included original studies investigating fatigue manifestations in patients with acromegaly, including epidemiological studies, psychometric validation reports, and intervention ...

Marea Therapeutics, Inc., a clinical-stage biotechnology company harnessing the latest advances in human genetics to develop first-in-class, next-generation medicines for cardioendocrine diseases ...

Familial acromegaly has been recognized for many years and, more recently, the clinical features of this clinical phenotype, referred to as isolated familial somatotropinoma, have been clarified.

Upcoming market catalysts in the third quarter of 2025 include US approval decisions on sepiapterin for phenylketonuria (PKU), apitegromab for spinal muscular atrophy (SMA) and paltusotine for ...